Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YV4F
|
|||
| Former ID |
DCL000581
|
|||
| Drug Name |
Ocrelizumab
|
|||
| Synonyms |
Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 202.8, 340] | Approved | [1] | |
| Multiple sclerosis [ICD-11: 8A40] | Approved | [2] | ||
| Company |
Roche/Genentech
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [3], [4] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018 | |||
| REF 3 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. | |||
| REF 4 | Clinical pipeline report, company report or official report of Roche (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.